NATICK, Mass., Sept. 14 Boston ScientificCorporation (NYSE: BSX) today released data reflecting experience from thefirst 15,000 patients(1) monitored wirelessly on the LATITUDE(R) PatientManagement System. This event data represents the industry's largestexperience with wireless remote monitoring of implantable cardiac devices.The LATITUDE Patient Management system can detect clinical events betweenscheduled follow-up visits and then send the clinical event data directly tophysicians. Virtually all Boston Scientific ICD and CRT-D patients areeligible to be enrolled on LATITUDE. To date, more than 60,000 patients areenrolled on the system at more than 1,300 clinics across the United States.
Of the nearly 106,000 monitoring months included in the 15,000-patientpopulation, over a mean follow-up of seven months, the LATITUDE PatientManagement system detected 948 patients with at least one event of sustainedatrial arrhythmia for more than 24 hours. Patients with atrial fibrillation,particularly those with heart failure, are at risk of stroke. By identifyingthis arrhythmia earlier, physicians can intervene with treatments to lessenthis risk. The LATITUDE Patient Management system also detected 1,516patients who received at least one event of shock therapy for potentially lifethreatening arrhythmias.
"Remote monitoring between regularly scheduled follow-ups may enableclinicians to observe these events sooner in their device patients, whichgives physicians the option to intervene earlier," said Mark A. Silver, M.D.,Director, Heart Failure Institute, Advocate Christ Medical Center, Oak Lawn,IL. "Equally important is regular monitoring of a patient's weight and bloodpressure, which are key indicators of potential heart failure in patients."Heart failure has an annual direct cost of more than $26 billion in the U.S.
Available as an optional component to the LATITUDE Patient Managementsystem is the industry's first and only wireless weight scale and bloodpressure cuff, which is aligned with the ACC/AHA physician society guidelinesthat recommend monitoring weight and blood pressure. LATITUDE also offerscustom views with relevant clinical data to both the implanting and healthcare following physicians. This feature, combined with passive eventnotification, is designed to improve patient care.
The LATITUDE Patient Management system will be demonstrated during theHeart Failure Society of America (HFSA) Conference, September 16-19, inWashington, DC.
Boston Scientific is a worldwide developer, manufacturer and marketer ofmedical devices whose products are used in a broad range of interventionalmedical specialties. For more information, please visit:www.bostonscientific.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaningof Section 21E of the Securities Exchange Act of 1934. Forward-lookingstatements may be identified by words like "anticipate," "expect," "project,""believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates usinginformation available to us at the time and are not intended to be guaranteesof future events or performance. These forward-looking statements include,among other things, statements regarding our product performance, significanceof event data, our growth strategy, our operational strategy, and our marketposition. If our underlying assumptions turn out to be incorrect, or ifcertain risks or uncertainties materialize, actual results could varymaterially from the expectations and projections expressed or implied by ourforward-looking statements. These factors, in some cases, have affected andin the future (together with other factors) could affect our ability toimplement our business strategy and may cause actual results to dif